HC Wainwright Issues Optimistic Outlook for VYGR Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Voyager Therapeutics in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.29) per share for the quarter, up from their prior forecast of ($0.39). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.32) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.25) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($1.17) EPS, FY2029 earnings at ($0.98) EPS and FY2030 earnings at ($0.55) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.08. The business had revenue of $3.17 million for the quarter, compared to analysts’ expectations of $4.52 million. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 54.82%.

A number of other brokerages have also weighed in on VYGR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Voyager Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Trading Up 0.9%

Shares of NASDAQ VYGR opened at $3.20 on Wednesday. Voyager Therapeutics has a 12 month low of $2.93 and a 12 month high of $5.55. The firm has a market capitalization of $193.35 million, a PE ratio of -1.78 and a beta of 1.31. The firm has a fifty day simple moving average of $3.38 and a two-hundred day simple moving average of $3.73.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wexford Capital LP bought a new position in Voyager Therapeutics in the third quarter worth $42,000. ProShare Advisors LLC bought a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $44,000. CIBC Asset Management Inc bought a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $45,000. Coldstream Capital Management Inc. purchased a new stake in shares of Voyager Therapeutics in the 3rd quarter worth about $55,000. Finally, Ieq Capital LLC purchased a new stake in shares of Voyager Therapeutics in the 2nd quarter worth about $48,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics News Roundup

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright raised EPS forecasts across multiple periods. The firm improved its estimates for Q3 and Q4 2026, every quarter of 2027, and fiscal years 2026 through 2030. Notably, its FY2026 loss estimate improved to $1.32 per share from $1.61, FY2027 to $1.06 from $1.18, FY2028 to $1.17 from $1.63, FY2029 to $0.98 from $1.38, and FY2030 to $0.55 from $0.94. Although Voyager is still expected to report losses, the revisions suggest HC Wainwright sees a less severe earnings trajectory than previously anticipated.
• Positive Sentiment: HC Wainwright maintained its “Buy” rating. The repeated estimate increases and reaffirmed bullish rating provide a favorable sentiment catalyst for VYGR, particularly for a small-cap biotechnology company whose valuation is sensitive to analyst expectations. HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics
• Neutral Sentiment: Short-interest data offers little trading signal. Reported short interest was zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. This indicates no measurable short-covering or elevated bearish positioning to materially influence the shares.
• Negative Sentiment: Voyager remains unprofitable. HC Wainwright’s revised forecasts still call for losses through 2030, while the consensus current-year estimate remains a $1.39-per-share loss. The company’s limited revenue base and ongoing cash-burn risk remain important counterweights to the improved estimates.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.